Zacks Small-Cap Research: “MTST: Lab Receives State License, Last Major Before CLIA Certification”

NEW YORK, NY / ACCESSWIRE / September 29, 2015 / Market Exclusive announces that Zacks Small-Cap Research has reiterated a Buy rating of MetaStat, Inc. (OTCQB: MTST) to with a 12-month price target of $0.75 per share. The analyst note was published following MetaStat’s newly announced Massachusetts state clinical laboratory license, a commercial milestone towards attaining CLIA certification.

Outlining the importance of MetaStat’s new state lab license, Zacks analyst Brian Marckx, CFA writes, “This is the last major step before receiving CLIA certification from CMS…The state licensure follows on the heels of studies validating the performance and accuracy of MTST’s fully automated MetaSite Breast assay.”

About Market Exclusive

Market Exclusive Is a financial portal geared to engaging discussion on current financial topics. Market Exclusive is not an investment advisor.

The owner of this announcement warrants that: (i) the releases contained herein are protected by copyright and other applicable laws; and (ii) they are solely responsible for the content, accuracy and originality of the information contained therein.

SOURCE: Market Exclusive

ReleaseID: 432302